Impaired Renal Function/Kidney Disease Single Dose Study

Last updated: N/A
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

N/A

Condition

Renal Failure

Kidney Disease

Kidney Failure (Pediatric)

Treatment

N/A

Clinical Study ID

TX264160
  • Ages 18-79
  • All Genders

Study Summary

Single-Dose Study to Evaluate participants with normal Renal Function and Renal Impairment

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Be aged 18 through 79 years of age
  • Participants have not donated blood within 56 days of study entry or plasma within 7 days of study entry and must refrain from blood donation from study center admission, throughout the study period, and continuing for at least 30 days following the last dose of study drug
  • Have renal impairment classification at screening that has been unchanged during the 3 months prior to screening

Exclusion

Exclusion Criteria:

Study Design

Study Start date:
January 26, 2021
Estimated Completion Date:

Study Description

A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of XXXX and Metabolites in Participants with Normal Renal Function and Renal Impairment

Connect with a study center

  • Advanced Pharma - Miami

    Miami, Florida 33147
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.